Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02420730 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye
A Phase 1 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
NCT02420730 is a Phase 1 study that has completed, run by Allergan. The registered enrollment target is 77 participants.
The verdict
NCT02420730, a Phase 1 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
This study will examine the safety, tolerability, and systemic pharmacokinetics of up to 3 different concentrations of AGN-232411 topical ophthalmic solution in healthy participants and participants with dry eye.
Interventions
- DRUG AGN-232411
- DRUG AGN-232411 Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2015-06 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02420730
The ClinicalTrials.gov registry entry for NCT02420730 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AGN-232411 is the first listed.
NCT02420730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02420730 about?
NCT02420730 is a clinical study titled "Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye". This study will examine the safety, tolerability, and systemic pharmacokinetics of up to 3 different concentrations of AGN-232411 topical ophthalmic solution in healthy participants and participants with dry eye.
What is the current status of trial NCT02420730?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2015-06. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02420730?
The interventions under investigation include: AGN-232411 (DRUG), AGN-232411 Vehicle (DRUG).
Who is sponsoring clinical trial NCT02420730?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.